Optimizing Novel Heterobifunctional Degraders – An Update

• Overview of Astellas’ TPD approach to overcome undruggable targets
• Updating next-generation degrader candidates
• Emerging DAC approaches to deliver TPD molecules to tumor tissues

Speakers:

Takashi Sugane

Head, Candidate Delivery, Engineered Small Molecules

Astellas Pharma